Literature DB >> 884665

Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells.

K K Tsuboi, N H Edmunds, L K Kwong.   

Abstract

A highly selective inhibition of de novo pyrimidine synthesis in the intact cell has been demonstrated by the action of N-(phosphonacetyl)-L-aspartate (PALA), a transition-state analog inhibitor of the reaction catalyzed by asparate transcarbamylase. The effect of pyrimidine deprivation induced by this agent on the viability and survival of human normal (WI-38) and colonic cancer cells (HT-29) was examined. The PALA-treated, pyrimidine-deprived cells failed to grow but demonstrated a normal rate of glucose utilization with impaired glycogen synthesis. Pyrimidine deprivation and lack of cell growth were maintained long after PALA removal. Growth inhibition of HT-29 cells by PALA was found to reflect an apparent steady state between newly formed and dying cells induced by limited pyrimidine availability. The highly selective nature of PALA action was confirmed by the ability of an exogenous source of pyrimidine to restore the normal growth pattern of the cell. Significant antitumor activity of PALA was found against a transplantable colonic tumor (line 26) carried in mice.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 884665

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Expression, purification, crystallization and preliminary X-ray diffraction analysis of the aspartate transcarbamoylase domain of human CAD.

Authors:  Alba Ruiz-Ramos; Nada Lallous; Araceli Grande-García; Santiago Ramón-Maiques
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-11-29

2.  N-phosphonacetyl-L-isoasparagine a potent and specific inhibitor of Escherichia coli aspartate transcarbamoylase.

Authors:  Joby Eldo; James P Cardia; Elizabeth M O'Day; Jiarong Xia; Hiro Tsuruta; Evan R Kantrowitz
Journal:  J Med Chem       Date:  2006-10-05       Impact factor: 7.446

3.  Comparison of the bioavailability of uridine in mice after either oral or parenteral administration.

Authors:  P Klubes; D B Geffen; R L Cysyk
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.